Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2000 1
2014 1
2015 1
2016 1
2017 1
2018 4
2019 1
2021 1
2022 2
2023 1
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem.
Mefford B, Wallace KL, Donaldson JC, Bissell Turpin BD, Sen P, Schadler AD, Liu LJ, Thompson Bastin ML. Mefford B, et al. Antimicrob Agents Chemother. 2024 May 2;68(5):e0108523. doi: 10.1128/aac.01085-23. Epub 2024 Apr 12. Antimicrob Agents Chemother. 2024. PMID: 38606975
Piperacillin-tazobactam (TZP), cefepime (FEP), or meropenem (MEM) and vancomycin (VAN) are commonly used in combination for sepsis. ...The odds of developing MAKE-30 were not different between any group and FEP/MEM/AUC. The effect …
Piperacillin-tazobactam (TZP), cefepime (FEP), or meropenem (MEM) and vancomycin (VAN) are commonly used in c …
Impact of Acquired Broad Spectrum beta-Lactamases on Susceptibility to Novel Combinations Made of beta-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel beta-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
Le Terrier C, Nordmann P, Freret C, Seigneur M, Poirel L. Le Terrier C, et al. Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. doi: 10.1128/aac.00339-23. Epub 2023 May 31. Antimicrob Agents Chemother. 2023. PMID: 37255469 Free PMC article.
The impact of broad-spectrum beta-lactamases on the susceptibility to novel beta-lactamase/beta-lactamase inhibitor combinations was evaluated both in Pseudomonas aeruginosa and Escherichia coli using isogenic backgrounds. Cefepime-zidebactam displayed low MICs, mai …
The impact of broad-spectrum beta-lactamases on the susceptibility to novel beta-lactamase/beta-lactamase inhibitor combinations was …
Meropenem-ANT3310, a unique beta-lactam-beta-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii.
Zalacain M, Achard P, Llanos A, Morrissey I, Hawser S, Holden K, Toomey E, Davies D, Leiris S, Sable C, Ledoux A, Bousquet J, Castandet J, Lozano C, Everett M, Lemonnier M. Zalacain M, et al. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0112023. doi: 10.1128/aac.01120-23. Epub 2024 Jan 30. Antimicrob Agents Chemother. 2024. PMID: 38289044 Free PMC article.
MEM was poorly active against A. baumannii, as were MEM-vaborbactam, ceftazidime-avibactam, aztreonam-avibactam, cefepime-taniborbactam, cefepime-zidebactam, and imipenem-relebactam (MIC(90) values of 32 g/mL). ...This study demonstrates the potent in vitro activity …
MEM was poorly active against A. baumannii, as were MEM-vaborbactam, ceftazidime-avibactam, aztreonam-avibactam, cefepime-taniborbact …
Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
Kiley PS, Pearston AP, Hodge LA, Kaplan MC, Baczek SM, Stanley JS, Wilson TJ, Soriano KM, Yao A, Shaeffer ZA, Talt IE, Cohen JA, Ingemi AI. Kiley PS, et al. Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0004022. doi: 10.1128/aac.00040-22. Epub 2022 Jul 13. Antimicrob Agents Chemother. 2022. PMID: 35867523 Free PMC article.
Acute kidney injury (AKI) is a complication associated with vancomycin. Previous studies demonstrated that the combination of vancomycin and piperacillin-tazobactam increases the risk of AKI compared to vancomycin wit …
Acute kidney injury (AKI) is a complication associated with vancomycin. Previous studies demonstrated that the combi …
Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam.
Satapoomin N, Dulyayangkul P, Avison MB. Satapoomin N, et al. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0217921. doi: 10.1128/aac.02179-21. Epub 2022 Mar 16. Antimicrob Agents Chemother. 2022. PMID: 35293781 Free PMC article.
We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system) exhibits resistance to ceftazid …
We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has …
Convulsive liability of cefepime and meropenem in normal and corneal kindled mice.
Tanaka A, Takechi K, Watanabe S, Tanaka M, Suemaru K, Araki H. Tanaka A, et al. Antimicrob Agents Chemother. 2014 Aug;58(8):4380-3. doi: 10.1128/AAC.02862-14. Epub 2014 May 19. Antimicrob Agents Chemother. 2014. PMID: 24841261 Free PMC article.
We have reported significantly higher convulsion prevalence in patients treated with cefepime than in those treated with meropenem. Additionally, cefepime-associated convulsions were found only in patients with brain disorders, not renal failure. ...We also m …
We have reported significantly higher convulsion prevalence in patients treated with cefepime than in those treated with meropenem. A …
Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation.
D'Cunha R, Bach T, Young BA, Li P, Nalbant D, Zhang J, Winokur P, An G. D'Cunha R, et al. Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00861-18. doi: 10.1128/AAC.00861-18. Print 2018 Sep. Antimicrob Agents Chemother. 2018. PMID: 29941653 Free PMC article.
Although the stability of beta-lactam antibiotics is a known issue, none of the previously reported bioanalytical methods had an adequate evaluation of the stability of these drugs. In the current study, the stability of cefepime, meropenem, piperacillin, and taz …
Although the stability of beta-lactam antibiotics is a known issue, none of the previously reported bioanalytical methods had an adequate ev …
Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin.
Rutter WC, Burgess DS. Rutter WC, et al. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00264-18. doi: 10.1128/AAC.00264-18. Print 2018 Jul. Antimicrob Agents Chemother. 2018. PMID: 29712661 Free PMC article.
Acute kidney injury (AKI) increases during empirical antimicrobial therapy with the combination of piperacillin-tazobactam (TZP) and vancomycin (VAN) compared to the number of incidences with monotherapy or the combination of cefepime …
Acute kidney injury (AKI) increases during empirical antimicrobial therapy with the combination of piperacillin-tazo …
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, Potoski BA, Kreiswirth BN, Clancy CJ, Nguyen MH. Buehrle DJ, et al. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May. Antimicrob Agents Chemother. 2016. PMID: 26976862 Free PMC article.
We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. ...Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% o …
We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MI …
Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum beta-lactamases.
Le Terrier C, Nordmann P, Buchs C, Poirel L. Le Terrier C, et al. Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0154823. doi: 10.1128/aac.01548-23. Epub 2024 Feb 28. Antimicrob Agents Chemother. 2024. PMID: 38415988
The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified in Escherichia coli was evaluated with respect to susceptibility to beta-lactam/beta-lactamase inhibitor combinations including ceftazidime-avibactam, imipenem-relebactam, meropen …
The impact of penicillin-binding protein 3 (PBP3) modifications that may be identified in Escherichia coli was evaluated with respect …
20 results